The history of leukemia ICD-10 coding runs parallel to the history of the disease itself. As doctors learned to tell leukemias apart, first by how cells looked and later by their genes, the International Classification of Diseases added codes to match. Today, leukemia ICD-10 codes sit in the C91–C95 range, and they record not only the type of leukemia but whether it is active, in remission, or relapsed. This article traces that path from first description to modern treatment.
What Leukemia Is
Leukemia is a group of hematological cancers that start in the bone marrow. Abnormal blood-forming cells multiply without control and crowd out normal production of white and red blood cells and platelets.
Leukemias are sorted along two lines. Acute leukemias involve immature cells (blasts) and progress quickly; chronic leukemias involve more mature cells and usually progress slowly. They are also split by cell lineage: lymphoid or myeloid. That gives the four main types: ALL, AML, CLL, and CML. Our leukemia guide covers each in depth.
Most leukemias have no single identifiable cause. Known risk factors include high-dose ionizing radiation, benzene exposure, previous chemotherapy, and some inherited conditions such as Down syndrome. Many of the key drivers are acquired changes in the leukemia cells themselves, like the Philadelphia chromosome in CML.
Symptoms reflect the marrow failing to make normal cells: tiredness and pallor from anemia, infections from a lack of working white cells, and easy bruising or bleeding from low platelets. Acute leukemias tend to cause these symptoms over weeks, while chronic leukemias are often found by chance on a routine blood test.
From “White Blood” to a Named Disease
In the 1840s, pathologists including Rudolf Virchow in Germany and John Hughes Bennett in Scotland described patients whose blood was thick with white cells. Virchow named the condition leukämie, from the Greek for “white blood.” For the next century, leukemia was recognized mainly by the microscope and was almost always fatal.
The science moved in steps. Stains made different white cells easier to distinguish, which allowed acute and chronic forms, and lymphoid and myeloid forms, to be separated. You can read more about these early milestones in our history of leukemia overview.
Key milestones at a glance
| Era | Milestone |
|---|---|
| 1840s | Leukemia described and named by Virchow and Bennett |
| Late 1940s | First chemotherapy remissions in childhood ALL with antifolate drugs |
| 1960 | Philadelphia chromosome identified in CML |
| 1973 | Philadelphia chromosome shown to be a 9;22 translocation |
| 1976 | French-American-British (FAB) classification of acute leukemias |
| 1990s | ICD-10 introduced by WHO member states |
| 2001 | WHO classification of hematologic cancers; imatinib approved for CML |
| 2015 | United States moves to ICD-10-CM |
| 2017 | First CAR T-cell therapy approved, for relapsed childhood ALL |
How ICD Coding for Leukemia Evolved
In ICD-9, leukemias were coded 204 to 208 by cell type: lymphoid, myeloid, monocytic, other specified, and unspecified. ICD-10 kept that logic but moved leukemia into the neoplasm chapter with alphanumeric codes, which made room for more detail.
| ICD-10 category | Covers | Common examples |
|---|---|---|
| C91 | Lymphoid leukemia | C91.0 ALL; C91.1 CLL of B-cell type |
| C92 | Myeloid leukemia | C92.0 AML; C92.1 CML, BCR-ABL1 positive |
| C93 | Monocytic leukemia | Chronic myelomonocytic leukemia |
| C94 | Other leukemias of specified cell type | Acute megakaryoblastic leukemia |
| C95 | Leukemia of unspecified cell type | Used when the type is not documented |
The US clinical modification, ICD-10-CM, adds a final character for disease status: 0 for not having achieved remission, 1 for in remission, and 2 for in relapse. So C91.00 means ALL that is active, while C91.01 means ALL in remission. For practical rules on choosing these codes, see our article on ICD-10 coding and classification in leukemia management.
How Diagnosis Advanced
Modern diagnosis of leukemia still begins with a complete blood count and a look at the blood smear. Typical clues are a very high or very low white count, circulating blasts, anemia, and a low platelet count.
Confirmation comes from bone marrow aspiration and biopsy. On top of the microscope, labs now add:
- Flow cytometry, which identifies the cell lineage from surface markers.
- Cytogenetics, which looks for chromosome changes such as the Philadelphia chromosome.
- Molecular testing (PCR and next-generation sequencing), which finds gene mutations such as FLT3 or NPM1 in AML.
These tools are why classification shifted from appearance alone, as in the FAB system, to the genetic definitions used in the WHO classification. The story of CML shows this best; our article on diagnosing chronic myeloid leukemia explains how the BCR-ABL1 test confirms it.
How Treatment Advanced
Treatment followed the same arc, from broad attack to precise targeting. Combination chemotherapy turned childhood ALL from a fatal disease into one that is now cured in most children. Stem cell transplantation gave some patients with high-risk disease a chance of cure.
The biggest shift came with targeted therapy. Tyrosine kinase inhibitors such as imatinib block the abnormal BCR-ABL1 protein in CML, and many patients now live near-normal lifespans on daily tablets. Acute promyelocytic leukemia, once one of the most dangerous leukemias, is now highly curable with all-trans retinoic acid and arsenic trioxide.
More recently, immunotherapy has joined the list. CAR T-cell therapy re-engineers a patient’s own T cells to attack leukemia and is used for certain relapsed or resistant B-cell ALL. Targeted drugs for specific AML mutations have also expanded options for older adults who cannot tolerate intensive chemotherapy.
Why the Coding History Matters Today
Accurate codes do more than support billing. They let cancer registries track how many people develop each leukemia, how treatments perform, and how survival changes over time. The remission and relapse characters in ICD-10-CM make that tracking more meaningful.
Leukemia coding is one part of the wider field of hematology, and it keeps changing. WHO’s ICD-11, in effect since 2022, restructures blood cancer codes again to reflect genetic subtypes more closely.
Key Takeaways
- Leukemia was first described in the 1840s and was classified by microscope for over a century.
- ICD-10 codes leukemia in categories C91 to C95 by cell type; ICD-10-CM adds remission and relapse status.
- Diagnosis now combines blood counts, bone marrow biopsy, flow cytometry, cytogenetics, and molecular testing.
- Treatment has moved from chemotherapy alone to targeted drugs, transplant, and immunotherapy.
Frequently Asked Questions
What ICD-10 codes are used for leukemia?
Leukemia falls under C91 (lymphoid), C92 (myeloid), C93 (monocytic), C94 (other specified cell types), and C95 (unspecified). The subcode identifies the exact type, such as C92.0 for AML.
What does the last digit in a leukemia ICD-10-CM code mean?
In the US version, the final character records disease status: 0 means not in remission, 1 means in remission, and 2 means relapsed. It must be updated as the patient’s status changes.
Why did leukemia classification move toward genetics?
Leukemias that look alike under the microscope can behave very differently and respond to different drugs. Genetic findings predict outcome and guide treatment, so modern classifications build them into the definitions.
Has leukemia treatment really improved?
Yes. Most children with ALL are now cured, many people with CML live near-normal lives on targeted tablets, and APL is highly curable. Outcomes in some types, especially AML in older adults, remain harder, which is where current research is focused.
